Overview
This is the multi-centered, open, prospective and retrospective study of up to total 120 subjects in breast reconstruction surgery with applying acellular dermal matrix(ADM). The aim of the study is to ascertain any difference in the rate of complications between the test group of undergoing breast reconstruction with SC Derm and the control group of taking breast reconstruction with other ADM products.
Description
In South Korea, breast reconstruction surgery using implants or autologous abdominal tissue is commonly performed as the standard treatment to address the aesthetic and psychological needs of breast cancer patients who have undergone total mastectomies. In this procedure, acellular dermal matrix (ADM) is used to compensate for the skin deficit resulting from the removal of cancerous tissue. This clinical study is designed to ascertain whether there are differences in clinical efficacy, aesthetic outcomes, and safety in breast reconstruction surgery using ADM processed with supercritical carbon dioxide technology compared to other ADMs. The test group will be prospectively selected in 60 patients who undergo the breast reconstruction surgery applying with SC Derm(Inverstigational ADM processed by the supercritical technology). The control group will be retrospectively collected in 60 patients who underwent the breast reconstruction surgery applying with other ADM from the current medical records for one year of 2022.
Eligibility
Inclusion Criteria:
- Female patients aged 20 to 69 scheduled for total mastectomy
- Patients who are willing to undergo immediate breast reconstruction using implants.
Exclusion Criteria:
- Patients who have undergone organ transplantation and are currently taking immunosuppressive medication.
- Patients with mental conditions that could impact the conduct of the clinical study, such as alcohol or drug abuse.
- Patients who have participated in another clinical trial within 120 days prior to screening.
- Any other cases where the investigator deems the patient unsuitable for this clinical study.